Literature DB >> 19300409

Amplification and co-regulators of androgen receptor gene in prostate cancer.

Ch Golias1, I Iliadis, D Peschos, K Charalabopoulos.   

Abstract

Prostate cancer is the second most common malignancy among males after lung cancer. The growth of prostate cancer cells depends on the presence of androgens, a group of steroid hormones that include testosterone and its more active metabolite dihydrotestoste-rone. Most prostate cancers are androgen-dependent and respond to the antiandrogens or androgen-deprivation therapy. However, the progression to an androgen-independent stage occurs frequently. Possible mechanisms that could be involved in the development of hormone resistant prostate cancer causes including androgen receptor (AR) mutations, AR amplification/over expression, interaction between AR and other growth factors, and enhanced signaling in a ligand-independent manner are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19300409

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  12 in total

1.  MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor.

Authors:  Fajun Qu; Xingang Cui; Yi Hong; Junkai Wang; Yao Li; Lu Chen; Yushan Liu; Yi Gao; Danfeng Xu; Quanxing Wang
Journal:  Mol Cell Biochem       Date:  2013-02-17       Impact factor: 3.396

2.  Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy.

Authors:  Tong Sun; Gwo-Shu Mary Lee; Lillian Werner; Mark Pomerantz; William K Oh; Philip W Kantoff; Matthew L Freedman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07       Impact factor: 4.254

3.  Androgen receptor molecular biology and potential targets in prostate cancer.

Authors:  Elizabeth M Wilson
Journal:  Ther Adv Urol       Date:  2010-06

4.  Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models.

Authors:  Giovanni Luca Gravina; Francesco Marampon; Margherita Piccolella; Marcella Motta; Luca Ventura; Roberto Pomante; Vladimir M Popov; Bianca M Zani; Richard G Pestell; Vincenzo Tombolini; Emmanuele A Jannini; Claudio Festuccia
Journal:  Endocrinology       Date:  2011-10-11       Impact factor: 4.736

5.  Copper signaling axis as a target for prostate cancer therapeutics.

Authors:  Rachid Safi; Erik R Nelson; Satish K Chitneni; Katherine J Franz; Daniel J George; Michael R Zalutsky; Donald P McDonnell
Journal:  Cancer Res       Date:  2014-10-15       Impact factor: 12.701

6.  HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling.

Authors:  Young-Rang Kim; Kyung-Jin Oh; Ra-Young Park; Nguyen Thi Xuan; Taek-Won Kang; Dong-Deuk Kwon; Chan Choi; Min Soo Kim; Kwang Il Nam; Kyu Youn Ahn; Chaeyong Jung
Journal:  Mol Cancer       Date:  2010-05-27       Impact factor: 27.401

7.  Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells.

Authors:  Wen-Chin Huang; Haiyen E Zhau; Leland W K Chung
Journal:  J Biol Chem       Date:  2010-01-13       Impact factor: 5.157

Review 8.  Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples.

Authors:  Hafiz Ahmed
Journal:  Biomark Cancer       Date:  2010-02-18

9.  Castration-resistant prostate cancer: potential targets and therapies.

Authors:  Aijaz Parray; Hifzur R Siddique; Sanjeev Nanda; Badrinath R Konety; Mohammad Saleem
Journal:  Biologics       Date:  2012-08-17

10.  To die or to survive, a fatal question for the destiny of prostate cancer cells after androgen deprivation therapy.

Authors:  Kai-Xin Zhang; Jessica Firus; Brenda Prieur; William Jia; Paul S Rennie
Journal:  Cancers (Basel)       Date:  2011-03-24       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.